Held by: VTI IWM VXF XBI IWN VTWO SCHA IWO VHT IWC | Scroll to Statements |
Index | RUT | P/E | 10.66 | EPS (ttm) | 0.59 | Insider Own | 21.82% | Shs Outstand | 146.23M | Perf Week | -2.19% |
Market Cap | 919.03M | Forward P/E | 19.81 | EPS next Y | 0.32 | Insider Trans | -0.26% | Shs Float | 114.78M | Perf Month | -14.13% |
Income | 85.55M | PEG | 0.71 | EPS next Q | 0.05 | Inst Own | 45.84% | Short Float | 4.22% | Perf Quarter | -20.66% |
Sales | 340.46M | P/S | 2.70 | EPS this Y | -27.03% | Inst Trans | 3.14% | Short Ratio | 6.74 | Perf Half Y | -24.03% |
Book/sh | 1.15 | P/B | 5.47 | EPS next Y | 17.04% | ROA | 42.55% | Short Interest | 4.85M | Perf Year | -14.95% |
Cash/sh | 0.47 | P/C | 13.31 | EPS next 5Y | 15.00% | ROE | 69.80% | 52W Range | 5.57 - 9.27 | Perf YTD | -28.62% |
Dividend Est. | - | P/FCF | 19.37 | EPS past 5Y | - | ROI | 45.93% | 52W High | -32.47% | Beta | 1.99 |
Dividend TTM | - | Quick Ratio | 3.22 | Sales past 5Y | -1.19% | Gross Margin | 83.19% | 52W Low | 12.39% | ATR (14) | 0.26 |
Dividend Ex-Date | - | Current Ratio | 3.85 | EPS Y/Y TTM | 496.65% | Oper. Margin | 18.57% | RSI (14) | 36.81 | Volatility | 2.97% 3.77% |
Employees | 895 | Debt/Eq | 0.11 | Sales Y/Y TTM | 15.41% | Profit Margin | 25.13% | Recom | 1.00 | Target Price | 12.20 |
Option/Short | Yes / Yes | LT Debt/Eq | 0.11 | EPS Q/Q | 2673.91% | Payout | 0.00% | Rel Volume | 0.43 | Prev Close | 6.27 |
Sales Surprise | -2.02% | EPS Surprise | 60.00% | Sales Q/Q | 7.32% | Earnings | Jul 31 AMC | Avg Volume | 719.28K | Price | 6.26 |
SMA20 | -8.88% | SMA50 | -9.64% | SMA200 | -15.97% | Trades | Volume | 311,741 | Change | -0.16% |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions withourpremium features. Real-time quotes, advancedvisualizations, backtesting, and much more.
Learn more about FINVIZ*Elite